Skip to main content
All lobbying filings

Terumo BCT, Inc.

Terumo BCT, Inc. filed a Q3 report for Terumo BCT, Inc. on October 21, 2025.

Lobbying for Terumo BCT, Inc. · Medical technology company

As filed: TERUMO BCT, INC. for TERUMO BCT, INC.

All filings by Terumo BCT, Inc. · Everything Terumo BCT, Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 21, 2025
Expenses
$20,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Colorado

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Trade (domestic/foreign)

Global trade and tariffs

Health Issues

S.721 - SCD Comprehensive Care Act S.752/H.R.1509 - Accelerating Kids Access to Care Act S.735/H.R. 1796 - Reauthorization of Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025 Blood and cell collection, storage, and processing Blood donation supply and quality

 Bills named in this filing 5
  • S. 721
    Sickle Cell Disease Comprehensive Care Act
  • S. 752
    Accelerating Kids’ Access to Care Act
  • H.R. 1509
    Accelerating Kids’ Access to Care Act of 2025
  • S. 735
    Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
  • H.R. 1796
    Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem